Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2016

View Archived Issues

Laboratorios del Dr. Esteve reports sigma1 and mu-opioid receptor ligands

Biorhythm patents L. plantarum strain to treat allergy

Igenica Biotherapeutics presents antineoplastic compounds

Aquinnah Pharmaceuticals reports TAR DNA-binding protein inhibitors

Prana Biotechnology divulges compounds for neurological disorders

Phase I results for new generation fluoroquinolone lascufloxacin

Arsanis MAbs target the LPS-O antigen of Klebsiella pneumoniae ST258

FDA approves Humira for intermediate, posterior and panuveitis

Positive opinion handed down for Belkyra through European decentralized procedure

European and Japanese approvals for Kyprolis in multiple myeloma

Lilly's ixekizumab approved in Japan

New aminomethylcycline shows efficacy in pneumonia murine models

BIND Therapeutics files motion for court approval of Pfizer stalking horse asset purchase agreement

Argenx reports promising initial results from multiple-ascending-dose phase I study of ARGX-113

Takeda files for Japanese approval of ixazomib for relapsed or refractory multiple myeloma

Vimpat approved in Japan as adjunctive therapy to treat partial onset seizures

Phase I results support further development of RE-024 for the potential treatment of PKAN

Soricimed Biopharma's SOR-C13 receives FDA orphan drug designation

Japan first to approve Lumicef worldwide

Evofosfamide in combination with sorafenib shows preliminary efficacy for HCC

PhaseBio initiates phase IIa trial of PB-1046 in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...